As per notification vide GSR No.332 (E) Dated 23 May 2013 Government had suspended the manufacture, sale and distribution of Dextropropoxyphene and formulations containing Dextropropoxyphene for human use.
Its sale already banned in the US, UK and other countries earlier.
Product permissions granted to the manufacturers and its loan licensees to manufacture this drug and its formulations also stand suspended.
The drug must be withdrawn from the market immediately as per notification of Government of India.
What a Revised Schedule M raises GMP standards in India, what has changed for manufacturers, and how large firms and MSMEs can prepare for Compliance and CDSCO inspections. Revised Schedule M is the b..
A practical comparison of CDSCO vs FDA vs EMA, explaining how each regulator’s Drug approval process differs and why one Drug needs separate approvals in India, the US and Europe. A Drug approve..
A quick guide on the Class A & B Medical Device manufacturing license — covering State FDA rules, Form MD-3/MD-5, fees, and timelines for manufacturers. Every manufacturer entering India’s..